Author:
Suvag Seda,Utzschneider Kristina M.,Kahn Steven E.
Reference168 articles.
1. Tjokroprawiro A (2006) New approach in the treatment of T2DM and metabolic syndrome (focus on a novel insulin sensitizer). Acta Med Indones 38(3):160–166
2. Nissen SE, Wolski K (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356(24):2457–2471
3. Update on ongoing European review of pioglitazone–containing medicines. 2011 [cited 2012 September 28]; Available from:
http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2011/06/WC500107515.pdf
.
4. Sakamoto J, Kimura H, Moriyama S, Odaka H, Momose Y, Sugiyama Y et al (2000) Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone. Biochem Biophys Res Commun 278(3):704–711
5. Kendall DM, Rubin CJ, Mohideen P, Ledeine JM, Belder R, Gross J et al (2006) Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a double-blind, randomized, pioglitazone-comparative study. Diabetes Care 29(5):1016–1023